Healthcare and Life Sciences

Format: 2017-02-22
Format: 2017-02-22
January 16, 2017 | 116 Pages | SKU: IRTNTR11577

Overview of the global pharmerging markets

Technavio’s market research analyst predicts the global pharmerging markets to grow steadily at a CAGR of around 13% by 2021. One of the primary drivers for this market is the increasing focus toward biosimilar in potential areas. As most of the patents for originator biologics have expired, the vendors are focusing on the development of duplicate copies of biologics, called biosimilars. These biosimilars provide the same efficacy as that of parent molecule but at a cheaper cost. The availability of cheap manufacturing resources such as land and labor has made the pharmerging market an important option for the development of these biosimilars. For instance, in 2014 trastuzumab, (a biosimilar of CANMab), which is indicated for the treatment of metastatic breast cancer was launched in India. Moreover, the on-going strong market growth in therapeutic areas will contribute further to higher penetration of the pharmerging markets over the next few years. 

One of the latest trends gaining traction in this market is the rise in the positive outlook through the adoption of targeted therapies. With the growing incidences of chronic diseases such as cancer, which requires specific therapies for effective treatment, the implementation of targeted therapies is expected to witness substantial upward momentum. Research studies have demonstrated that targeted therapy has increased the survival rate and the cure rate in cancer patients. These drugs are expected to work effectively in the treatment of various cancers such as


January 13, 2017 | 83 Pages | SKU: IRTNTR11535

Overview of the global compression therapy market

Technavio’s market research analyst predicts that the global compression therapy market will grow at a CAGR of more than 5% during the forecast period. The emergence of sequential compression therapy systems is anticipated to have a positive influence on the market, due to its growing use in several applications. Sequential calf compression and graduated compression stockings are increasingly being used for prophylaxis in neurosurgery for the prevention of PE and DVT. Also, the intraoperative sequential compression device systems are recommended during prolonged laparoscopic surgery to counter altered venous blood return from the lower extremities and subsequent cardiac depression caused by pneumoperitoneum. Sequential compression is an effective therapy, which generates results within 1-2 hours per day when compared to other alternatives that take 12-48 hours to achieve the same outcome. With an increase in the number of surgical procedures, the chances of developing thromboembolic events, which require treatment using compression therapy systems will also grow, further contributing to the growth of the overall market.

Geographically, the APAC region will witness the fastest growth rate in the global market during the forecast period. Much of the region’s growth can be attributed to the rising incidences of chronic conditions such as diabetes and VTE coupled with recent product innovations. The growing awareness among physicians about new compression systems will bring substantial growth opportunities in the market. Moreover, with the increasing demand for compression therapy in sports applications will further fuel the market growth in the APAC


January 13, 2017 | 123 Pages | SKU: IRTNTR11536

Overview of the global interventional cardiology market

The global interventional cardiology market is anticipated to grow at a steady rate and will post a CAGR of more than 7% during the forecast period. The growing demand for minimally invasive (MI) procedures will drive the growth prospects for the global interventional cardiology market in the forthcoming years. Some of the major factors responsible for the growing preference for MI includes faster recovery, less pain, fewer post-surgery infections, reduced hospital stays, minimized incision marks, controlled bleeding, and minimal complications and high accuracy. Also, MI artery stenting enhances the surgical precision by providing a 3D view of the patient and allowing the manipulation of small surgical tools for the placement of stents in the individual's body. As a result, 3D-MRI techniques for improved imaging has increased the popularity of MRI procedures, which will eventually increase the demand for cardiac surgeries.

The growing popularity of hybrid procedures will drive the growth prospects for the global industrial castings market over the next four years. According to the industry research report, one of the major factors responsible for the growing preference for hybrid procedures is their ability to eradicate plaque entirely from the blood vessels and offer qualitative results to patients.

Competitive landscape and key vendors

The global interventional cardiology market is highly competitive and diversified due to the presence


January 12, 2017 | 73 Pages | SKU: IRTNTR11520

Overview of the myasthenia gravis drugs market

Extensive research carried out by the market research analysts at Technavio has shown that the global myasthenia gravis drugs market will witness impressive growth and post a staggering CAGR of more than 13% over the forecast period. The market is witnessing the rapid development of novel drugs such as monoclonal antibodies, which is one of the primary factors driving this market’s growth prospects. Most drug manufacturers are increasingly focussing on the development of monoclonal antibodies, as they act specifically on target cells; thereby, leading to lower side effects. Since conventional therapies such as acetylcholinesterase inhibitor, oral steroids, and immunomodulatory agents are associated with more side effects, physicians prefer to prescribe high efficacious monoclonal antibodies. For instance, Soliris (eculizumab) is one such drug that is currently in Phase III development stage. The drug acts by restricting the disease cells from affecting the immune system. Soliris (eculizumab) is anticipated to receive approval by the end of 2017 or in early 2018 in the US. Some of the other monoclonal antibodies in the pipeline include Novartis' CFZ-533 and GlaxoSmithKline's Benlysta. With several monoclonal antibody-based drugs in the pipeline, the market for myasthenia gravis drugs will have a positive outlook in the coming years.

One of the recent trends gaining traction in the market is the growing number of strategic acquisitions in the market. Several vendors are looking to expand their product portfolio and market presence by pursuing inorganic growth strategies such as acquisitions. Such growth strategies allow companies to reduce R&D costs and quickly establish a presence in the


January 12, 2017 | 78 Pages | SKU: IRTNTR11500

Overview of the global immunodiagnostics market

The global immunodiagnostics market is anticipated to grow at a steady rate and will post a CAGR of close to 8% during the forecast period. The increasing adoption of point-of-care testing (POCT) will drive the growth prospects for the global immunodiagnostics market until the end of 2021. Some of the life-threatening conditions that need serious attention include sepsis and acute cardiac infarction. Such serious conditions with high mortality rate drive the necessity for POCT, which, in turn, boosts the demand for immunodiagnostics testing.  One of the areas of focus for traditional and non-traditional healthcare companies are POCT for cardiovascular biomarkers. Also, POCT is fast, accurate, portable, and simple to interpret, which helps healthcare providers in alternative healthcare settings. Moreover, the cost of POCT is very low because of its small capillary tubes that need fewer reagents.

In terms of geography, the Americas accounted for the maximum market share during 2016 and will continue to dominate the market for the next four years. The demand for diagnostic products and services in the region is growing because of factors such as the fast-growing elderly population and the high prevalence of chronic and infectious diseases. Also, the rising awareness of the diseases among consumers compels them to undergo regular tests and check-ups, which improves the sales of immunodiagnostic products in the US. Furthermore, increased FDA approval, shift to point-of-care (POC) rapid diagnostic tests and a rise in laboratory


January 12, 2017 | 85 Pages | SKU: IRTNTR11144

Overview of the global anesthesia drugs market

The global anesthesia drugs market is anticipated to grow at a steady rate and will post a CAGR of more than 3% during the forecast period. The growing volume of surgical procedures will drive the growth prospects for the global anesthesia drugs market in the coming years. Anesthesia is administered during various surgical procedures conducted to treat various diseases such as cardiovascular diseases, gastrointestinal diseases, urological disorders, spinal abnormalities, brain tumors, and orthopedic deformities. The rise in the number of surgical procedures in the European countries will aid in the growth of the market in these locations. For instance, the number of laparoscopic colectomy procedures doubled in Slovenia and tripled in Spain between 2008 and 2014.  Some of the surgeries performed in various ambulatory surgical centers (ASCs) include lens and cataract, hernia procedure, cervix and uterus removal, hysterectomy, and transurethral excision.

In terms of geography, the Americas accounted for the maximum market share during 2016 and will continue to dominate the market until the end of 2021. One of the major factors responsible for the market’s growth in the US is the growing demand for propofol. Additionally, the increasing focus of a large number of vendors towards exploring new routes of administration such as oral and topical will also drive the preference for anesthetic drugs in the market. Analysts predict that the increasing demand for anesthesia in labor will also drive market growth. According to the Centers for Disease Control and Prevention (CDC), the total number of deliveries including vaginal and caesarean stood at 3,984,


Pages